Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2021; 11(4):1546-1567. doi:10.7150/thno.48662 This issue Cite

Review

Nanomedicine of tyrosine kinase inhibitors

Veronika Smidova1, Petr Michalek1,2, Zita Goliasova1, Tomas Eckschlager3, Petr Hodek4, Vojtech Adam1,2, Zbynek Heger1,2✉

1. Department of Chemistry and Biochemistry Mendel University in Brno, Zemedelska 1, 613 00 Brno, Czech Republic.
2. Central European Institute of Technology, Brno University of Technology, Purkynova 656/123, 612 00 Brno, Czech Republic.
3. Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, and University Hospital Motol, V Uvalu 84, Prague 5 CZ-15006, Czech Republic.
4. Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, 128 40 Prague 2, Czech Republic.

✉ Corresponding author: Zbynek Heger, Department of Chemistry and Biochemistry, Mendel University in Brno, Zemedelska 1, CZ-613 00 Brno, Czech Republic; E-mail: hegercz; phone: +420-5-4513-3350; fax: +420-5-4521-2044.

Citation:
Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V, Heger Z. Nanomedicine of tyrosine kinase inhibitors. Theranostics 2021; 11(4):1546-1567. doi:10.7150/thno.48662. https://www.thno.org/v11p1546.htm
Other styles

File import instruction

Abstract

Graphic abstract

Recent progress in nanomedicine and targeted therapy brings new breeze into the field of therapeutic applications of tyrosine kinase inhibitors (TKIs). These drugs are known for many side effects due to non-targeted mechanism of action that negatively impact quality of patients' lives or that are responsible for failure of the drugs in clinical trials. Some nanocarrier properties provide improvement of drug efficacy, reduce the incidence of adverse events, enhance drug bioavailability, helps to overcome the blood-brain barrier, increase drug stability or allow for specific delivery of TKIs to the diseased cells. Moreover, nanotechnology can bring new perspectives into combination therapy, which can be highly efficient in connection with TKIs. Lastly, nanotechnology in combination with TKIs can be utilized in the field of theranostics, i.e. for simultaneous therapeutic and diagnostic purposes. The review provides a comprehensive overview of advantages and future prospects of conjunction of nanotransporters with TKIs as a highly promising approach to anticancer therapy.

Keywords: Bioavailability, Drug delivery, Nanotechnology, Targeted therapy

Citation styles

APA
Smidova, V., Michalek, P., Goliasova, Z., Eckschlager, T., Hodek, P., Adam, V., Heger, Z. (2021). Nanomedicine of tyrosine kinase inhibitors. Theranostics, 11(4), 1546-1567. https://doi.org/10.7150/thno.48662.

ACS
Smidova, V.; Michalek, P.; Goliasova, Z.; Eckschlager, T.; Hodek, P.; Adam, V.; Heger, Z. Nanomedicine of tyrosine kinase inhibitors. Theranostics 2021, 11 (4), 1546-1567. DOI: 10.7150/thno.48662.

NLM
Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V, Heger Z. Nanomedicine of tyrosine kinase inhibitors. Theranostics 2021; 11(4):1546-1567. doi:10.7150/thno.48662. https://www.thno.org/v11p1546.htm

CSE
Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V, Heger Z. 2021. Nanomedicine of tyrosine kinase inhibitors. Theranostics. 11(4):1546-1567.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use